Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATGC-100
- Development stage
- Phase 3
- Lead developer
- ATGC Co. Ltd
- Modality
- Recombinant Proteins and Enzymes, Peptides, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intramuscular, Intradermal, Intradetrusor
01
Overview
ATGC-100 is a novel formulation of botulinum toxin type A (900 kDa complex) developed for medical aesthetic indications, primarily to improve the appearance of moderate to severe glabellar frown lines. It acts as a neuromuscular blocker by inhibiting acetylcholine release at the neuromuscular junction through SNAP25 inhibition, resulting in temporary muscle paralysis and reduction of dynamic wrinkles. The product has demonstrated efficacy and safety comparable to established products like Allergan’s Botox in clinical trials. Developed using proprietary CHS2 technology by ATGC Co., Ltd., it is being advanced in partnership with EuBiologics and licensed for European development and commercialization by RELIFE S.r.l. (Menarini Group)[2][3][4][5].
- Other names
- Clostridium botulinum toxin type ABotulinum toxin type A (ATGC/EuBiologics)ATGC100ATGC-100ATGC 100
02
Targets
SNAP25 (Synaptosome-associated protein 25)
Beyond the preview
Go deeper on ATGC-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATGC-100.